Zahid Delwar, PhD
About Zahid Delwar, PhD
Zahid Delwar, PhD, is a scientist and group leader specializing in pharmacology and toxicology, with a focus on virology techniques for oncolytic virotherapy. He has extensive experience in biotech and pharmaceutical product development and has worked at several prestigious institutions, including The University of British Columbia and Virogin Biotech Ltd.
Work at Virogin Biotech
Zahid Delwar has been employed at Virogin Biotech Ltd since 2019, where he holds the position of Scientist and Group Leader in Pharmacology and Toxicology. In this role, he focuses on the development of oncolytic virotherapy strategies, leveraging his expertise in virology techniques. His work contributes to advancing therapeutic approaches in the biotech sector, particularly in cancer treatment.
Education and Expertise
Zahid Delwar earned his Doctor of Philosophy (Ph.D.) from The University of British Columbia, where he studied from 2011 to 2016. Prior to this, he completed his Master's degree at Linköping University from 2008 to 2010. His educational background is complemented by extensive expertise in laboratory animal models and in vivo techniques, which are essential for pharmacology and toxicology research.
Background
Zahid Delwar's professional journey includes various roles in research and business development. He worked as a Researcher at Karolinska Institutet in Stockholm, Sweden, for one year from 2010 to 2011. Before that, he served as a Business Development Executive at Beacon Pharmaceuticals Limited for five months in 2008. He also gained experience as a Graduate Student Researcher at Linköping University from 2009 to 2010 and as a Postdoctoral Researcher at Vancouver Prostate Centre from 2017 to 2019.
Achievements
Zahid Delwar has made significant contributions to the field of pharmacology and toxicology, particularly in the area of oncolytic virotherapy. He has published research on HER2-expressing Oncolytic Herpes Simplex Virus, which induces immune responses against HER2-positive tumor cells. In addition, he co-authored a publication in 2023, further demonstrating his active engagement in research and development within the biotech industry.